drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00252 | DB11979 | 362 | 1,320 | [
"DDInter1460",
"DDInter625"
] | Phenytoin | Elagolix | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
362,
24,
1320
]
],
[
[
362,
64,
168
],
[
168,
23,
1320
]
],
[
[
362,
23,
608
],
[
608,
23,
1320
]
],
[
[
362,
25,
1297
],
[
1297,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
... | Phenytoin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Phenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor in... |
DB00054 | DB11689 | 1,432 | 321 | [
"DDInter6",
"DDInter1659"
] | Abciximab | Selumetinib | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
1432,
24,
321
]
],
[
[
1432,
25,
291
],
[
291,
24,
321
]
],
[
[
1432,
25,
1421
],
[
1421,
63,
321
]
],
[
[
1432,
24,
1061
],
[
1061,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban"... | Abciximab may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Abciximab may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate inter... |
DB00774 | DB06203 | 1,577 | 1,002 | [
"DDInter889",
"DDInter51"
] | Hydroflumethiazide | Alogliptin | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1577,
24,
1002
]
],
[
[
1577,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1577,
21,
28873
],
[
28873,
60,
1002
]
],
[
[
1577,
40,
504
],
[
5... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Hydroflumethiazide (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Alogliptin (Compound)
Hydroflumethiazide (... |
DB00748 | DB00832 | 662 | 499 | [
"DDInter297",
"DDInter1446"
] | Carbinoxamine | Phensuximide | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Phensuximide is a member of the succinimide class with anticonvulsant properties. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. | Moderate | 1 | [
[
[
662,
24,
499
]
],
[
[
662,
63,
902
],
[
902,
40,
499
]
],
[
[
662,
24,
157
],
[
157,
40,
499
]
],
[
[
662,
6,
10215
],
[
10215,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phensuximide"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Phensuximide (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin (Compound) resembles Phensuximide (Compound... |
DB00802 | DB01612 | 1,322 | 1,637 | [
"DDInter43",
"DDInter92"
] | Alfentanil | Amyl Nitrite | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
1322,
24,
1637
]
],
[
[
1322,
63,
475
],
[
475,
24,
1637
]
],
[
[
1322,
24,
401
],
[
401,
24,
1637
]
],
[
[
1322,
25,
593
],
[
593,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promet... |
DB00465 | DB09030 | 886 | 840 | [
"DDInter1010",
"DDInter1945"
] | Ketorolac | Vorapaxar | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
886,
25,
840
]
],
[
[
886,
24,
885
],
[
885,
24,
840
]
],
[
[
886,
63,
1061
],
[
1061,
24,
840
]
],
[
[
886,
24,
738
],
[
738,
6... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprosteno... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Tre... |
DB00307 | DB01229 | 1,101 | 973 | [
"DDInter202",
"DDInter1377"
] | Bexarotene | Paclitaxel | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
1101,
24,
973
]
],
[
[
1101,
24,
310
],
[
310,
63,
973
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
973
]
],
[
[
1101,
21,
29267
],
[
29267,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Bexarotene (Comp... |
DB00295 | DB00370 | 475 | 1,251 | [
"DDInter1244",
"DDInter1230"
] | Morphine | Mirtazapine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Moderate | 1 | [
[
[
475,
24,
1251
]
],
[
[
475,
24,
830
],
[
830,
40,
1251
]
],
[
[
475,
6,
3486
],
[
3486,
45,
1251
]
],
[
[
475,
21,
29250
],
[
29250,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine (Compound) resembles Mirtazapine (Compound)
Morphine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Mirtazapine (Compound)
Morphine (Compound) causes Polyuria (Side Effect) and Polyuria (... |
DB00795 | DB09291 | 50 | 741 | [
"DDInter1725",
"DDInter1615"
] | Sulfasalazine | Rolapitant | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
50,
24,
741
]
],
[
[
50,
24,
1180
],
[
1180,
63,
741
]
],
[
[
50,
63,
1252
],
[
1252,
24,
741
]
],
[
[
50,
25,
1510
],
[
1510,
2... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
],
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant and Rimegepant may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Dig... |
DB00213 | DB11791 | 837 | 785 | [
"DDInter1388",
"DDInter287"
] | Pantoprazole | Capmatinib | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Minor | 0 | [
[
[
837,
23,
785
]
],
[
[
837,
1,
1215
],
[
1215,
23,
785
]
],
[
[
837,
24,
98
],
[
98,
24,
785
]
],
[
[
837,
63,
600
],
[
600,
24,
... | [
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capmatinib"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a m... | Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that cou... |
DB00783 | DB01222 | 1,438 | 617 | [
"DDInter679",
"DDInter246"
] | Estradiol | Budesonide | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1438,
24,
617
]
],
[
[
1438,
63,
251
],
[
251,
1,
617
]
],
[
[
1438,
24,
1220
],
[
1220,
1,
617
]
],
[
[
1438,
6,
8374
],
[
8374,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (... |
DB00215 | DB00501 | 1,230 | 752 | [
"DDInter388",
"DDInter380"
] | Citalopram | Cimetidine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Major | 2 | [
[
[
1230,
25,
752
]
],
[
[
1230,
6,
4973
],
[
4973,
45,
752
]
],
[
[
1230,
18,
6351
],
[
6351,
57,
752
]
],
[
[
1230,
21,
29134
],
[
29134... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidin... | Citalopram (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cimetidine (Compound)
Citalopram (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Cimetidine (Compound)
Citalopram (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Ci... |
DB01125 | DB06605 | 279 | 1,409 | [
"DDInter98",
"DDInter108"
] | Anisindione | Apixaban | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
279,
25,
1409
]
],
[
[
279,
64,
86
],
[
86,
24,
1409
]
],
[
[
279,
63,
723
],
[
723,
24,
1409
]
],
[
[
279,
25,
609
],
[
609,
24... | [
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} m... | Anisindione may lead to a major life threatening interaction when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause ... |
DB06674 | DB12674 | 908 | 975 | [
"DDInter837",
"DDInter1105"
] | Golimumab | Lurbinectedin | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Major | 2 | [
[
[
908,
25,
975
]
],
[
[
908,
64,
1488
],
[
1488,
24,
975
]
],
[
[
908,
25,
1362
],
[
1362,
24,
975
]
],
[
[
908,
63,
522
],
[
522,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u... | Golimumab may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Golimumab may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate inter... |
DB01126 | DB01128 | 1,260 | 918 | [
"DDInter611",
"DDInter204"
] | Dutasteride | Bicalutamide | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
1260,
24,
918
]
],
[
[
1260,
24,
129
],
[
129,
40,
918
]
],
[
[
1260,
6,
8374
],
[
8374,
45,
918
]
],
[
[
1260,
21,
29232
],
[
29232,
... | [
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Dutasteride (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Dutasteride (Compound) causes Urticaria (Side Effect) an... |
DB00446 | DB00916 | 597 | 112 | [
"DDInter351",
"DDInter1202"
] | Chloramphenicol | Metronidazole | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
597,
24,
112
]
],
[
[
597,
24,
458
],
[
458,
40,
112
]
],
[
[
597,
6,
3486
],
[
3486,
45,
112
]
],
[
[
597,
21,
28778
],
[
28778,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Chloramphenicol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Chloramphenicol (Compound) causes Anaphylactic sho... |
DB06414 | DB09098 | 655 | 98 | [
"DDInter703",
"DDInter1700"
] | Etravirine | Somatrem | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
655,
24,
98
]
],
[
[
655,
63,
608
],
[
608,
23,
98
]
],
[
[
655,
62,
168
],
[
168,
23,
98
]
],
[
[
655,
24,
159
],
[
159,
63,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Etravirine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may... |
DB01174 | DB11967 | 697 | 710 | [
"DDInter1442",
"DDInter210"
] | Phenobarbital | Binimetinib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
697,
24,
710
]
],
[
[
697,
25,
1593
],
[
1593,
24,
710
]
],
[
[
697,
63,
883
],
[
883,
24,
710
]
],
[
[
697,
24,
1619
],
[
1619,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Cri... | Phenobarbital may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may c... |
DB00704 | DB04951 | 267 | 187 | [
"DDInter1263",
"DDInter1477"
] | Naltrexone | Pirfenidone | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
267,
24,
187
]
],
[
[
267,
63,
168
],
[
168,
23,
187
]
],
[
[
267,
24,
637
],
[
637,
63,
187
]
],
[
[
267,
24,
463
],
[
463,
24,... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia c... |
DB00026 | DB10795 | 1,184 | 221 | [
"DDInter94",
"DDInter1486"
] | Anakinra | Poliovirus type 1 antigen (formaldehyde inactivated) | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1184,
24,
221
]
],
[
[
1184,
24,
36
],
[
36,
24,
221
]
],
[
[
1184,
25,
581
],
[
581,
24,
221
]
],
[
[
1184,
24,
351
],
[
351,
6... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Anakinra may lead to a major life threatening interaction when taken with In... |
DB00477 | DB09078 | 216 | 1,228 | [
"DDInter363",
"DDInter1036"
] | Chlorpromazine | Lenvatinib | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
216,
24,
1228
]
],
[
[
216,
23,
112
],
[
112,
23,
1228
]
],
[
[
216,
24,
609
],
[
609,
24,
1228
]
],
[
[
216,
35,
820
],
[
820,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],... | Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromy... |
DB00317 | DB00992 | 883 | 842 | [
"DDInter810",
"DDInter1182"
] | Gefitinib | Methyl aminolevulinate (topical) | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
883,
24,
842
]
],
[
[
883,
21,
29124
],
[
29124,
60,
842
]
],
[
[
883,
24,
1622
],
[
1622,
24,
842
]
],
[
[
883,
63,
1101
],
[
1101,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Gefitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Rash pustular"
],
[
"Rash pustular",
"{u} (Si... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Gefitinib (Compound) causes Rash pustular (Side Effect) and Rash pustular (Side Effect) is caused by Methyl aminolevulinate (Compound)
Gefitinib may cause a moderate interaction that could exacerbate disease... |
DB00572 | DB06077 | 85 | 879 | [
"DDInter136",
"DDInter1102"
] | Atropine | Lumateperone | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
85,
24,
879
]
],
[
[
85,
24,
407
],
[
407,
63,
879
]
],
[
[
85,
24,
1511
],
[
1511,
24,
879
]
],
[
[
85,
63,
999
],
[
999,
24,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Op... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may c... |
DB00738 | DB01155 | 485 | 872 | [
"DDInter1420",
"DDInter813"
] | Pentamidine | Gemifloxacin | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Moderate | 1 | [
[
[
485,
24,
872
]
],
[
[
485,
24,
739
],
[
739,
1,
872
]
],
[
[
485,
25,
945
],
[
945,
40,
872
]
],
[
[
485,
64,
1176
],
[
1176,
1,... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Pentamidine may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound)
P... |
DB00208 | DB00834 | 1,018 | 932 | [
"DDInter1804",
"DDInter1215"
] | Ticlopidine | Mifepristone | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Major | 2 | [
[
[
1018,
25,
932
]
],
[
[
1018,
6,
12523
],
[
12523,
45,
932
]
],
[
[
1018,
21,
28762
],
[
28762,
60,
932
]
],
[
[
1018,
24,
848
],
[
848... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mif... | Ticlopidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mifepristone (Compound)
Ticlopidine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Mifepristone (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and ... |
DB11627 | DB11714 | 1,367 | 1,316 | [
"DDInter860",
"DDInter610"
] | Hepatitis B Vaccine (Recombinant) | Durvalumab | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
1367,
24,
1316
]
],
[
[
1367,
63,
167
],
[
167,
24,
1316
]
],
[
[
1367,
24,
270
],
[
270,
63,
1316
]
],
[
[
1367,
63,
976
],
[
976,
... | [
[
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken... | Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exa... |
DB00468 | DB01226 | 1,424 | 1,319 | [
"DDInter1557",
"DDInter1235"
] | Quinine | Mivacurium | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Moderate | 1 | [
[
[
1424,
24,
1319
]
],
[
[
1424,
6,
4304
],
[
4304,
45,
1319
]
],
[
[
1424,
21,
28921
],
[
28921,
60,
1319
]
],
[
[
1424,
23,
1620
],
[
1... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mivacurium"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"... | Quinine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Mivacurium (Compound)
Quinine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Mivacurium (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline ma... |
DB00331 | DB00902 | 1,645 | 104 | [
"DDInter1164",
"DDInter1168"
] | Metformin | Methdilazine | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1645,
24,
104
]
],
[
[
1645,
24,
820
],
[
820,
1,
104
]
],
[
[
1645,
24,
401
],
[
401,
63,
104
]
],
[
[
1645,
24,
417
],
[
417,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that... |
DB06603 | DB09078 | 39 | 1,228 | [
"DDInter1387",
"DDInter1036"
] | Panobinostat | Lenvatinib | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
39,
25,
1228
]
],
[
[
39,
62,
112
],
[
112,
23,
1228
]
],
[
[
39,
64,
463
],
[
463,
23,
1228
]
],
[
[
39,
64,
1100
],
[
1100,
24... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Panobinostat may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may ... |
DB00962 | DB01069 | 1,639 | 401 | [
"DDInter1957",
"DDInter1533"
] | Zaleplon | Promethazine | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1639,
24,
401
]
],
[
[
1639,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1639,
21,
28709
],
[
28709,
60,
401
]
],
[
[
1639,
63,
701
],
[
701,... | [
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"... | Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Zaleplon (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Prometha... |
DB01144 | DB09038 | 1,326 | 1,450 | [
"DDInter540",
"DDInter636"
] | Diclofenamide | Empagliflozin | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1326,
24,
1450
]
],
[
[
1326,
24,
659
],
[
659,
63,
1450
]
],
[
[
1326,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1326,
24,
885
],
[
885,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil... |
DB00434 | DB00633 | 13 | 614 | [
"DDInter459",
"DDInter520"
] | Cyproheptadine | Dexmedetomidine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Moderate | 1 | [
[
[
13,
24,
614
]
],
[
[
13,
6,
7390
],
[
7390,
45,
614
]
],
[
[
13,
21,
28741
],
[
28741,
60,
614
]
],
[
[
13,
24,
222
],
[
222,
63... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v}... | Cyproheptadine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Dexmedetomidine (Compound)
Cyproheptadine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Dexmedetomidine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00758 | DB11793 | 1,347 | 738 | [
"DDInter413",
"DDInter1297"
] | Clopidogrel | Niraparib | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1347,
24,
738
]
],
[
[
1347,
25,
1213
],
[
1213,
24,
738
]
],
[
[
1347,
64,
1578
],
[
1578,
24,
738
]
],
[
[
1347,
24,
463
],
[
463,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib"... | Clopidogrel may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Clopidogrel may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interac... |
DB00489 | DB13142 | 17 | 841 | [
"DDInter1704",
"DDInter274"
] | Sotalol | Calcium glubionate anhydrous | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
17,
24,
841
]
],
[
[
17,
1,
88
],
[
88,
24,
841
]
],
[
[
17,
62,
1152
],
[
1152,
24,
841
]
],
[
[
17,
1,
88
],
[
88,
40,
8... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cau... | Sotalol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Sotalol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interact... |
DB00370 | DB09082 | 1,251 | 659 | [
"DDInter1230",
"DDInter1934"
] | Mirtazapine | Vilanterol | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1251,
24,
659
]
],
[
[
1251,
24,
1220
],
[
1220,
23,
659
]
],
[
[
1251,
24,
927
],
[
927,
63,
659
]
],
[
[
1251,
25,
1069
],
[
1069,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and... |
DB00842 | DB04837 | 686 | 649 | [
"DDInter1359",
"DDInter407"
] | Oxazepam | Clofedanol | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feat... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
686,
24,
649
]
],
[
[
686,
24,
1376
],
[
1376,
24,
649
]
],
[
[
686,
63,
832
],
[
832,
40,
649
]
],
[
[
686,
63,
701
],
[
701,
2... | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
... | Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine ... |
DB11791 | DB12267 | 785 | 1,476 | [
"DDInter287",
"DDInter233"
] | Capmatinib | Brigatinib | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
785,
24,
1476
]
],
[
[
785,
62,
1135
],
[
1135,
23,
1476
]
],
[
[
785,
63,
629
],
[
629,
24,
1476
]
],
[
[
785,
62,
379
],
[
379,
... | [
[
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Capmatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Capmatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may... |
DB01128 | DB14723 | 918 | 159 | [
"DDInter204",
"DDInter1026"
] | Bicalutamide | Larotrectinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
918,
24,
159
]
],
[
[
918,
23,
907
],
[
907,
23,
159
]
],
[
[
918,
62,
479
],
[
479,
23,
159
]
],
[
[
918,
25,
318
],
[
318,
23,... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepe... |
DB00736 | DB01076 | 660 | 700 | [
"DDInter676",
"DDInter133"
] | Esomeprazole | Atorvastatin | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
660,
24,
700
]
],
[
[
660,
6,
10215
],
[
10215,
45,
700
]
],
[
[
660,
63,
126
],
[
126,
23,
700
]
],
[
[
660,
63,
467
],
[
467,
... | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Esomeprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Com... | Esomeprazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Atorvastatin (Compound)
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Atorvastatin
Esomeprazole m... |
DB00224 | DB09039 | 215 | 1,670 | [
"DDInter917",
"DDInter629"
] | Indinavir | Eliglustat | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
215,
25,
1670
]
],
[
[
215,
25,
1135
],
[
1135,
62,
1670
]
],
[
[
215,
24,
1409
],
[
1409,
24,
1670
]
],
[
[
215,
24,
1499
],
[
1499,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may c... | Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate... |
DB00708 | DB08904 | 1,454 | 375 | [
"DDInter1718",
"DDInter342"
] | Sufentanil | Certolizumab pegol | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
1454,
24,
375
]
],
[
[
1454,
1,
704
],
[
704,
24,
375
]
],
[
[
1454,
63,
58
],
[
58,
24,
375
]
],
[
[
1454,
24,
1303
],
[
1303,
... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sufentanil",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a mod... | Sufentanil (Compound) resembles Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that cou... |
DB00108 | DB06603 | 1,066 | 39 | [
"DDInter1268",
"DDInter1387"
] | Natalizumab | Panobinostat | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1066,
25,
39
]
],
[
[
1066,
64,
912
],
[
912,
24,
39
]
],
[
[
1066,
24,
221
],
[
221,
63,
39
]
],
[
[
1066,
25,
1683
],
[
1683,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon be... | Natalizumab may lead to a major life threatening interaction when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type ... |
DB06772 | DB14409 | 310 | 1,129 | [
"DDInter259",
"DDInter867"
] | Cabazitaxel | Human adenovirus e serotype 4 strain cl-68578 antigen | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
310,
24,
1129
]
],
[
[
310,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
310,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
310,
24,
1468
],
[
1468,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Cabazitaxel may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when ta... |
DB00407 | DB09075 | 202 | 498 | [
"DDInter115",
"DDInter621"
] | Ardeparin | Edoxaban | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
202,
25,
498
]
],
[
[
202,
24,
116
],
[
116,
63,
498
]
],
[
[
202,
24,
222
],
[
222,
24,
498
]
],
[
[
202,
63,
1595
],
[
1595,
2... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131... | Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibut... |
DB01259 | DB08875 | 392 | 1,618 | [
"DDInter1024",
"DDInter262"
] | Lapatinib | Cabozantinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
392,
25,
1618
]
],
[
[
392,
23,
1135
],
[
1135,
62,
1618
]
],
[
[
392,
62,
112
],
[
112,
23,
1618
]
],
[
[
392,
63,
723
],
[
723,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazo... |
DB09073 | DB15982 | 951 | 1,339 | [
"DDInter1379",
"DDInter193"
] | Palbociclib | Berotralstat | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Major | 2 | [
[
[
951,
25,
1339
]
],
[
[
951,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
951,
24,
283
],
[
283,
23,
1339
]
],
[
[
951,
63,
761
],
[
761,
... | [
[
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexaro... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedr... |
DB06228 | DB06674 | 792 | 908 | [
"DDInter1609",
"DDInter837"
] | Rivaroxaban | Golimumab | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
792,
24,
908
]
],
[
[
792,
63,
1461
],
[
1461,
23,
908
]
],
[
[
792,
63,
336
],
[
336,
24,
908
]
],
[
[
792,
64,
697
],
[
697,
2... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipin... |
DB01236 | DB08871 | 679 | 36 | [
"DDInter1664",
"DDInter666"
] | Sevoflurane | Eribulin | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
679,
24,
36
]
],
[
[
679,
63,
1424
],
[
1424,
24,
36
]
],
[
[
679,
24,
820
],
[
820,
24,
36
]
],
[
[
679,
24,
28
],
[
28,
63,
... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
... | Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine... |
DB10316 | DB11760 | 334 | 119 | [
"DDInter1248",
"DDInter1742"
] | Mumps virus strain B level jeryl lynn live antigen | Talazoparib | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Major | 2 | [
[
[
334,
25,
119
]
],
[
[
334,
64,
599
],
[
599,
24,
119
]
],
[
[
334,
25,
351
],
[
351,
24,
119
]
],
[
[
334,
25,
1619
],
[
1619,
6... | [
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when ... | Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threaten... |
DB00307 | DB01254 | 1,101 | 1,213 | [
"DDInter202",
"DDInter484"
] | Bexarotene | Dasatinib | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1101,
24,
1213
]
],
[
[
1101,
5,
11555
],
[
11555,
44,
1213
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
1101,
21,
28882
],
[
2... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Bexarotene",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease... | Bexarotene (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Bexarotene (Compound) causes Body temperature increased (Side Effect) and Body temperature increased ... |
DB12865 | DB14012 | 922 | 349 | [
"DDInter688",
"DDInter253"
] | Etelcalcetide | Burosumab | Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. | Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the fi... | Moderate | 1 | [
[
[
922,
24,
349
]
],
[
[
922,
64,
1008
],
[
1008,
24,
1065
],
[
1065,
25,
349
]
]
] | [
[
[
"Etelcalcetide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Burosumab"
]
],
[
[
"Etelcalcetide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risedronic acid"
],
[
"... | Etelcalcetide may lead to a major life threatening interaction when taken with Risedronic acid and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate and Calcium Phosphate may lead to a major life threatening interaction when taken with Burosumab |
DB06589 | DB09481 | 1,250 | 460 | [
"DDInter1400",
"DDInter1113"
] | Pazopanib | Magnesium carbonate | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1250,
24,
460
]
],
[
[
1250,
63,
401
],
[
401,
23,
460
]
],
[
[
1250,
64,
752
],
[
752,
23,
460
]
],
[
[
1250,
24,
263
],
[
263,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Pazopanib may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine m... |
DB08871 | DB09472 | 36 | 1,383 | [
"DDInter666",
"DDInter1693"
] | Eribulin | Sodium sulfate | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
36,
24,
1383
]
],
[
[
36,
63,
609
],
[
609,
24,
1383
]
],
[
[
36,
24,
1612
],
[
1612,
63,
1383
]
],
[
[
36,
64,
607
],
[
607,
24... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir a... |
DB00515 | DB00736 | 589 | 660 | [
"DDInter387",
"DDInter676"
] | Cisplatin | Esomeprazole | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Moderate | 1 | [
[
[
589,
24,
660
]
],
[
[
589,
63,
1215
],
[
1215,
40,
660
]
],
[
[
589,
24,
379
],
[
379,
40,
660
]
],
[
[
589,
63,
837
],
[
837,
1... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Esomeprazole (Co... |
DB01105 | DB01309 | 222 | 1,254 | [
"DDInter1665",
"DDInter933"
] | Sibutramine | Insulin glulisine | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
222,
24,
1254
]
],
[
[
222,
24,
280
],
[
280,
63,
1254
]
],
[
[
222,
63,
1645
],
[
1645,
24,
1254
]
],
[
[
222,
24,
266
],
[
266,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Metfor... |
DB00486 | DB01174 | 1,614 | 697 | [
"DDInter1253",
"DDInter1442"
] | Nabilone | Phenobarbital | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
1614,
24,
697
]
],
[
[
1614,
24,
759
],
[
759,
1,
697
]
],
[
[
1614,
63,
362
],
[
362,
1,
697
]
],
[
[
1614,
63,
536
],
[
536,
4... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
Na... |
DB08881 | DB11793 | 868 | 738 | [
"DDInter1925",
"DDInter1297"
] | Vemurafenib | Niraparib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
868,
24,
738
]
],
[
[
868,
24,
466
],
[
466,
63,
738
]
],
[
[
868,
64,
1213
],
[
1213,
24,
738
]
],
[
[
868,
63,
663
],
[
663,
2... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Vemurafenib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cau... |
DB01033 | DB01208 | 328 | 945 | [
"DDInter1156",
"DDInter1705"
] | Mercaptopurine | Sparfloxacin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Minor | 0 | [
[
[
328,
23,
945
]
],
[
[
328,
62,
739
],
[
739,
1,
945
]
],
[
[
328,
23,
1539
],
[
1539,
1,
945
]
],
[
[
328,
21,
28787
],
[
28787,
... | [
[
[
"Mercaptopurine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Mercaptopurine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
... | Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) resembles Sparfloxacin (... |
DB09038 | DB11791 | 1,450 | 785 | [
"DDInter636",
"DDInter287"
] | Empagliflozin | Capmatinib | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1450,
24,
785
]
],
[
[
1450,
24,
1320
],
[
1320,
63,
785
]
],
[
[
1450,
63,
850
],
[
850,
24,
785
]
],
[
[
1450,
24,
98
],
[
98,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin... |
DB00106 | DB00845 | 618 | 1,490 | [
"DDInter4",
"DDInter406"
] | Abarelix | Clofazimine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Moderate | 1 | [
[
[
618,
24,
1490
]
],
[
[
618,
23,
112
],
[
112,
62,
1490
]
],
[
[
618,
24,
1250
],
[
1250,
63,
1490
]
],
[
[
618,
24,
51
],
[
51,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clofazimine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopani... |
DB00734 | DB00863 | 1,664 | 1,194 | [
"DDInter1605",
"DDInter1568"
] | Risperidone | Ranitidine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Minor | 0 | [
[
[
1664,
23,
1194
]
],
[
[
1664,
6,
8374
],
[
8374,
45,
1194
]
],
[
[
1664,
18,
5833
],
[
5833,
57,
1194
]
],
[
[
1664,
21,
29090
],
[
29... | [
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ranitidine (Compound)
Risperidone (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Ranitidine (Compound)
Risperidone (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Ranitid... |
DB01064 | DB01124 | 1,148 | 1,411 | [
"DDInter987",
"DDInter1828"
] | Isoprenaline | Tolbutamide | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1148,
24,
1411
]
],
[
[
1148,
24,
959
],
[
959,
40,
1411
]
],
[
[
1148,
63,
245
],
[
245,
40,
1411
]
],
[
[
1148,
21,
28762
],
[
28762... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Comp... |
DB00549 | DB01097 | 522 | 1,377 | [
"DDInter1955",
"DDInter1033"
] | Zafirlukast | Leflunomide | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
522,
25,
1377
]
],
[
[
522,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
522,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
522,
24,
242
],
[
242,
... | [
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Lefl... | Zafirlukast (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Zafirlukast (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir... |
DB00365 | DB13074 | 839 | 877 | [
"DDInter842",
"DDInter1110"
] | Grepafloxacin | Macimorelin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
839,
25,
877
]
],
[
[
839,
23,
112
],
[
112,
23,
877
]
],
[
[
839,
24,
1479
],
[
1479,
24,
877
]
],
[
[
839,
25,
913
],
[
913,
2... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Me... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicy... |
DB00312 | DB01069 | 1,023 | 401 | [
"DDInter1423",
"DDInter1533"
] | Pentobarbital | Promethazine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1023,
24,
401
]
],
[
[
1023,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1023,
24,
104
],
[
104,
24,
401
]
],
[
[
1023,
21,
28787
],
[
28787,... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Me... |
DB00026 | DB00075 | 1,184 | 541 | [
"DDInter94",
"DDInter1250"
] | Anakinra | Muromonab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Moderate | 1 | [
[
[
1184,
24,
541
]
],
[
[
1184,
23,
1193
],
[
1193,
62,
541
]
],
[
[
1184,
24,
270
],
[
270,
63,
541
]
],
[
[
1184,
25,
1066
],
[
1066,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Muromonab"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Muromonab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocreli... |
DB00529 | DB05812 | 789 | 1,374 | [
"DDInter779",
"DDInter8"
] | Foscarnet | Abiraterone | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
789,
24,
1374
]
],
[
[
789,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
789,
23,
112
],
[
112,
23,
1374
]
],
[
[
789,
63,
1494
],
[
1494,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Hypokalaemia"
],
[
"Hypokalaemia",
"{u} (Side Effect) is... | Foscarnet (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with ... |
DB05015 | DB06168 | 1,077 | 1,531 | [
"DDInter174",
"DDInter281"
] | Belinostat | Canakinumab | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1077,
24,
1531
]
],
[
[
1077,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
1077,
63,
599
],
[
599,
24,
1531
]
],
[
[
1077,
24,
1683
],
[
1683... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protei... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Belinostat may cause a moderate interaction that could ... |
DB06168 | DB12240 | 1,531 | 110 | [
"DDInter281",
"DDInter1485"
] | Canakinumab | Polatuzumab vedotin | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
1531,
24,
110
]
],
[
[
1531,
63,
467
],
[
467,
24,
110
]
],
[
[
1531,
25,
980
],
[
980,
24,
110
]
],
[
[
1531,
24,
951
],
[
951,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab and Tociliz... |
DB11853 | DB12245 | 230 | 823 | [
"DDInter1577",
"DDInter1863"
] | Relugolix | Triclabendazole | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
230,
24,
823
]
],
[
[
230,
62,
112
],
[
112,
23,
823
]
],
[
[
230,
63,
1010
],
[
1010,
24,
823
]
],
[
[
230,
24,
971
],
[
971,
2... | [
[
[
"Relugolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Relugolix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Relugolix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and M... |
DB00445 | DB00480 | 322 | 1,668 | [
"DDInter655",
"DDInter1035"
] | Epirubicin | Lenalidomide | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Moderate | 1 | [
[
[
322,
24,
1668
]
],
[
[
322,
25,
770
],
[
770,
40,
1668
]
],
[
[
322,
5,
11555
],
[
11555,
44,
1668
]
],
[
[
322,
18,
20113
],
[
20113,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalido... | Epirubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound)
Epirubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lenalidomide (Compound)
Epirubicin (Compound) downregulates IER3 (... |
DB00333 | DB11978 | 576 | 124 | [
"DDInter1166",
"DDInter822"
] | Methadone | Glasdegib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
576,
25,
124
]
],
[
[
576,
23,
112
],
[
112,
23,
124
]
],
[
[
576,
64,
475
],
[
475,
24,
124
]
],
[
[
576,
25,
79
],
[
79,
24,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Methadone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Methadone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Methadone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a mod... |
DB06723 | DB08930 | 115 | 1,459 | [
"DDInter58",
"DDInter582"
] | Aluminum hydroxide | Dolutegravir | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Major | 2 | [
[
[
115,
25,
1459
]
],
[
[
115,
63,
478
],
[
478,
23,
1459
]
],
[
[
115,
62,
752
],
[
752,
23,
1459
]
],
[
[
115,
63,
1596
],
[
1596,
... | [
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolutegravir"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Cimetidin... |
DB00400 | DB01058 | 353 | 978 | [
"DDInter843",
"DDInter1510"
] | Griseofulvin | Praziquantel | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Moderate | 1 | [
[
[
353,
24,
978
]
],
[
[
353,
6,
7950
],
[
7950,
45,
978
]
],
[
[
353,
21,
28680
],
[
28680,
60,
978
]
],
[
[
353,
24,
1623
],
[
1623,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Praziquantel"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compo... | Griseofulvin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Praziquantel (Compound)
Griseofulvin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Praziquantel (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and... |
DB00708 | DB00758 | 1,454 | 1,347 | [
"DDInter1718",
"DDInter413"
] | Sufentanil | Clopidogrel | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
1454,
24,
1347
]
],
[
[
1454,
6,
8374
],
[
8374,
45,
1347
]
],
[
[
1454,
21,
28778
],
[
28778,
60,
1347
]
],
[
[
1454,
24,
578
],
[
57... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Sufentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Sufentanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clopidogrel (Compound)
Sufentanil (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Clopidogrel (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with... |
DB09143 | DB12095 | 313 | 179 | [
"DDInter1701",
"DDInter1760"
] | Sonidegib | Telotristat ethyl | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
313,
24,
179
]
],
[
[
313,
24,
214
],
[
214,
24,
179
]
],
[
[
313,
63,
1213
],
[
1213,
24,
179
]
],
[
[
313,
64,
1593
],
[
1593,
... | [
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib an... |
DB00964 | DB01041 | 1,617 | 770 | [
"DDInter110",
"DDInter1789"
] | Apraclonidine | Thalidomide | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1617,
24,
770
]
],
[
[
1617,
21,
28714
],
[
28714,
60,
770
]
],
[
[
1617,
24,
849
],
[
849,
63,
770
]
],
[
[
1617,
1,
876
],
[
876,
... | [
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Apraclonidine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is... | Apraclonidine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Thalidomide (Compound)
Apraclonidine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Th... |
DB00315 | DB00574 | 767 | 121 | [
"DDInter1969",
"DDInter717"
] | Zolmitriptan | Fenfluramine | Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptan... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Major | 2 | [
[
[
767,
25,
121
]
],
[
[
767,
24,
868
],
[
868,
63,
121
]
],
[
[
767,
63,
702
],
[
702,
24,
121
]
],
[
[
767,
25,
1039
],
[
1039,
6... | [
[
[
"Zolmitriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
]
],
[
[
"Zolmitriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vem... | Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide an... |
DB00252 | DB01067 | 362 | 959 | [
"DDInter1460",
"DDInter826"
] | Phenytoin | Glipizide | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
362,
24,
959
]
],
[
[
362,
63,
245
],
[
245,
40,
959
]
],
[
[
362,
24,
1411
],
[
1411,
1,
959
]
],
[
[
362,
6,
8374
],
[
8374,
4... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
... |
DB00647 | DB11837 | 675 | 1,297 | [
"DDInter528",
"DDInter1351"
] | Dextropropoxyphene | Osilodrostat | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
675,
24,
1297
]
],
[
[
675,
23,
112
],
[
112,
23,
1297
]
],
[
[
675,
25,
222
],
[
222,
23,
1297
]
],
[
[
675,
24,
578
],
[
578,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazo... | Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Dextropropoxyphene may lead to a major life threatening interaction when taken with Sibutramine and ... |
DB00850 | DB01105 | 1,630 | 222 | [
"DDInter1432",
"DDInter1665"
] | Perphenazine | Sibutramine | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1630,
24,
222
]
],
[
[
1630,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1630,
18,
7359
],
[
7359,
57,
222
]
],
[
[
1630,
21,
29356
],
[
29356... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Perphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Perphenazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Perphenazine (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Sibutramine (Compound)
Perphenazine (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect)... |
DB00865 | DB01124 | 939 | 1,411 | [
"DDInter187",
"DDInter1828"
] | Benzphetamine | Tolbutamide | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
939,
24,
1411
]
],
[
[
939,
24,
959
],
[
959,
40,
1411
]
],
[
[
939,
63,
245
],
[
245,
40,
1411
]
],
[
[
939,
21,
29232
],
[
29232,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Co... |
DB05812 | DB15822 | 1,374 | 69 | [
"DDInter8",
"DDInter1504"
] | Abiraterone | Pralsetinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
1374,
24,
69
]
],
[
[
1374,
24,
283
],
[
283,
24,
69
]
],
[
[
1374,
63,
1213
],
[
1213,
24,
69
]
],
[
[
1374,
25,
985
],
[
985,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasa... |
DB11915 | DB13074 | 1,293 | 877 | [
"DDInter1909",
"DDInter1110"
] | Valbenazine | Macimorelin | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1293,
25,
877
]
],
[
[
1293,
62,
112
],
[
112,
23,
877
]
],
[
[
1293,
64,
913
],
[
913,
24,
877
]
],
[
[
1293,
63,
1662
],
[
1662,
... | [
[
[
"Valbenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Valbenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Valbenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Valbenazine may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may... |
DB09389 | DB12267 | 517 | 1,476 | [
"DDInter1315",
"DDInter233"
] | Norgestrel | Brigatinib | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
517,
25,
1476
]
],
[
[
517,
63,
629
],
[
629,
24,
1476
]
],
[
[
517,
24,
1385
],
[
1385,
63,
1476
]
],
[
[
517,
62,
14
],
[
14,
... | [
[
[
"Norgestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",... | Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglu... |
DB00387 | DB01114 | 1,386 | 272 | [
"DDInter1528",
"DDInter362"
] | Procyclidine | Chlorpheniramine | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1386,
24,
272
]
],
[
[
1386,
40,
11268
],
[
11268,
1,
272
]
],
[
[
1386,
24,
849
],
[
849,
63,
272
]
],
[
[
1386,
24,
128
],
[
128,
... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound)",
"Cloperastine"
],
[
"Cloperastine",
"{u} (Comp... | Procyclidine (Compound) resembles Cloperastine (Compound) and Cloperastine (Compound) resembles Chlorpheniramine (Compound)
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00104 | DB06414 | 966 | 655 | [
"DDInter1323",
"DDInter703"
] | Octreotide | Etravirine | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
966,
24,
655
]
],
[
[
966,
21,
28723
],
[
28723,
60,
655
]
],
[
[
966,
25,
1101
],
[
1101,
23,
655
]
],
[
[
966,
24,
245
],
[
245,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Octreotide",
"{u} (Compound) causes {v} (Side Effect)",
"Malnutrition"
],
[
"Malnutrition",
"{u} (Side Effect) i... | Octreotide (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Etravirine (Compound)
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Octreot... |
DB00434 | DB01233 | 13 | 1,311 | [
"DDInter459",
"DDInter1197"
] | Cyproheptadine | Metoclopramide | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
13,
24,
1311
]
],
[
[
13,
6,
7992
],
[
7992,
45,
1311
]
],
[
[
13,
10,
11610
],
[
11610,
49,
1311
]
],
[
[
13,
21,
28691
],
[
28691,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (C... | Cyproheptadine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Metoclopramide (Compound)
Cyproheptadine (Compound) palliates migraine (Disease) and migraine (Disease) is palliated by Metoclopramide (Compound)
Cyproheptadine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by ... |
DB00661 | DB14568 | 122 | 982 | [
"DDInter1928",
"DDInter1000"
] | Verapamil | Ivosidenib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
122,
25,
982
]
],
[
[
122,
62,
1101
],
[
1101,
23,
982
]
],
[
[
122,
24,
976
],
[
976,
24,
982
]
],
[
[
122,
25,
543
],
[
543,
2... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
... | Verapamil may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib... |
DB00026 | DB01042 | 1,184 | 1,307 | [
"DDInter94",
"DDInter1144"
] | Anakinra | Melphalan | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
1184,
24,
1307
]
],
[
[
1184,
24,
168
],
[
168,
23,
1307
]
],
[
[
1184,
23,
1193
],
[
1193,
62,
1307
]
],
[
[
1184,
24,
66
],
[
66,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan
Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc glucon... |
DB00748 | DB00924 | 662 | 1,405 | [
"DDInter297",
"DDInter454"
] | Carbinoxamine | Cyclobenzaprine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Moderate | 1 | [
[
[
662,
24,
1405
]
],
[
[
662,
35,
649
],
[
649,
63,
1405
]
],
[
[
662,
1,
11296
],
[
11296,
1,
1405
]
],
[
[
662,
63,
1302
],
[
1302,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases w... | Carbinoxamine (Compound) resembles Clofedanol (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine
Carbinoxamine (Compound) resembles Bromodip... |
DB00909 | DB04837 | 306 | 649 | [
"DDInter1971",
"DDInter407"
] | Zonisamide | Clofedanol | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
306,
24,
649
]
],
[
[
306,
25,
1376
],
[
1376,
24,
649
]
],
[
[
306,
64,
832
],
[
832,
40,
649
]
],
[
[
306,
64,
701
],
[
701,
2... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
],
[
"Diphe... | Zonisamide may lead to a major life threatening interaction when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Zonisamide may lead to a major life threatening interaction when taken with Tripelennamine and Tripelennamine (Compou... |
DB00427 | DB01403 | 1,233 | 9 | [
"DDInter1879",
"DDInter1175"
] | Triprolidine | Methotrimeprazine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1233,
24,
9
]
],
[
[
1233,
24,
1178
],
[
1178,
40,
9
]
],
[
[
1233,
24,
401
],
[
401,
24,
9
]
],
[
[
1233,
24,
1630
],
[
1630,
1... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a modera... |
DB00307 | DB14443 | 1,101 | 987 | [
"DDInter202",
"DDInter1931"
] | Bexarotene | Vibrio cholerae CVD 103-HgR strain live antigen | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1101,
24,
987
]
],
[
[
1101,
24,
1480
],
[
1480,
24,
987
]
],
[
[
1101,
25,
1468
],
[
1468,
24,
987
]
],
[
[
1101,
64,
305
],
[
305,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bexarotene may lead to a major life threatening interaction when taken with Pon... |
DB00794 | DB11730 | 759 | 351 | [
"DDInter1521",
"DDInter1588"
] | Primidone | Ribociclib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
759,
25,
351
]
],
[
[
759,
25,
466
],
[
466,
62,
351
]
],
[
[
759,
24,
112
],
[
112,
23,
351
]
],
[
[
759,
24,
310
],
[
310,
24,... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u}... | Primidone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may ... |
DB09073 | DB11760 | 951 | 119 | [
"DDInter1379",
"DDInter1742"
] | Palbociclib | Talazoparib | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
951,
24,
119
]
],
[
[
951,
63,
66
],
[
66,
24,
119
]
],
[
[
951,
64,
441
],
[
441,
24,
119
]
],
[
[
951,
24,
1129
],
[
1129,
63,... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Palbociclib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may c... |
DB11703 | DB12500 | 405 | 283 | [
"DDInter9",
"DDInter714"
] | Acalabrutinib | Fedratinib | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
405,
25,
283
]
],
[
[
405,
25,
351
],
[
351,
23,
283
]
],
[
[
405,
64,
1593
],
[
1593,
23,
283
]
],
[
[
405,
24,
327
],
[
327,
2... | [
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
... | Acalabrutinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Acalabrutinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor int... |
DB01142 | DB09034 | 1,264 | 1,313 | [
"DDInter593",
"DDInter1733"
] | Doxepin | Suvorexant | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
1264,
24,
1313
]
],
[
[
1264,
24,
649
],
[
649,
24,
1313
]
],
[
[
1264,
24,
1619
],
[
1619,
63,
1313
]
],
[
[
1264,
63,
530
],
[
530,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"C... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may... |
DB00344 | DB00398 | 1,302 | 79 | [
"DDInter1543",
"DDInter1702"
] | Protriptyline | Sorafenib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
1302,
24,
79
]
],
[
[
1302,
6,
4973
],
[
4973,
45,
79
]
],
[
[
1302,
18,
3162
],
[
3162,
46,
79
]
],
[
[
1302,
18,
16896
],
[
16896,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound... | Protriptyline (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sorafenib (Compound)
Protriptyline (Compound) downregulates CCNH (Gene) and CCNH (Gene) is upregulated by Sorafenib (Compound)
Protriptyline (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Sorafenib (Compound)
Protriptyl... |
DB00556 | DB08899 | 1,262 | 129 | [
"DDInter1429",
"DDInter649"
] | Perflutren | Enzalutamide | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1262,
24,
129
]
],
[
[
1262,
24,
918
],
[
918,
1,
129
]
],
[
[
1262,
21,
29377
],
[
29377,
60,
129
]
],
[
[
1262,
23,
112
],
[
112,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Perflutren (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Perflutren may... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.